CY1121596T1 - Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα - Google Patents

Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα

Info

Publication number
CY1121596T1
CY1121596T1 CY20191100097T CY191100097T CY1121596T1 CY 1121596 T1 CY1121596 T1 CY 1121596T1 CY 20191100097 T CY20191100097 T CY 20191100097T CY 191100097 T CY191100097 T CY 191100097T CY 1121596 T1 CY1121596 T1 CY 1121596T1
Authority
CY
Cyprus
Prior art keywords
benzoxazinone
amids
salt
formula
endothelial
Prior art date
Application number
CY20191100097T
Other languages
English (en)
Inventor
Gavin O'mahony
Michael Kossenjans
Karl Edman
Johan Kajanus
Carl Anders Hogner
Philip Cornwall
Andrew Turner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1121596T1 publication Critical patent/CY1121596T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Αποκαλύπτονται ορισμένα παράγωγα αμιδίων βενζοξαζινόνης χημικού τύπου (I), ή φαρμακευτικά αποδεκτά άλατα αυτών, (Χημικού Τύπου (I)) που δρουν ως αλατοκορτικοειδείς (MR) ρυθμιστές υποδοχέα που μπορούν μειώσουν το οξειδωτικό στρες στο ενδοθήλιο και συνεπώς βελτιώνουν την αγγειακή λειτουργία, με μεθόδους για τη πιθανή θεραπευτική χρήση τους, με φαρμακευτικές συνθέσεις που τα περιέχουν και με διεργασίες για την προετοιμασία τέτοιων ενώσεων.
CY20191100097T 2014-06-30 2019-01-24 Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα CY1121596T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
CY1121596T1 true CY1121596T1 (el) 2020-05-29

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100097T CY1121596T1 (el) 2014-06-30 2019-01-24 Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα

Country Status (25)

Country Link
US (2) US10017502B2 (el)
EP (1) EP3160948B1 (el)
JP (1) JP6368383B2 (el)
KR (1) KR102012222B1 (el)
CN (1) CN106536491B (el)
AR (1) AR101036A1 (el)
AU (1) AU2015282450C1 (el)
CA (1) CA2953655C (el)
CY (1) CY1121596T1 (el)
DK (1) DK3160948T3 (el)
EA (1) EA029518B1 (el)
ES (1) ES2707726T3 (el)
HR (1) HRP20190147T1 (el)
HU (1) HUE042370T2 (el)
LT (1) LT3160948T (el)
ME (1) ME03316B (el)
MX (1) MX367404B (el)
PL (1) PL3160948T3 (el)
PT (1) PT3160948T (el)
RS (1) RS58274B1 (el)
SI (1) SI3160948T1 (el)
TR (1) TR201900659T4 (el)
TW (1) TWI677498B (el)
UY (1) UY36195A (el)
WO (1) WO2016001631A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3160948T3 (en) * 2014-06-30 2019-02-18 Astrazeneca Ab BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
AU2020202887B2 (en) 2019-08-30 2021-05-20 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
US20220023252A1 (en) 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022262736A1 (zh) 2021-06-15 2022-12-22 正大天晴药业集团股份有限公司 苯并恶嗪酮类衍生物
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
WO2024047574A1 (en) 2022-09-01 2024-03-07 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085868A1 (en) * 2001-04-23 2002-10-31 Astrazeneca Ab Benzoxazinone derivatives for use in the treatment of angiogenesis
EP1581529A1 (en) * 2002-12-20 2005-10-05 Warner-Lambert Company Benzoxazines and derivatives thereof as inhibitors of pi3ks
BRPI0513119A (pt) * 2004-07-14 2008-04-29 Ligand Pharm Inc compostos e métodos modulares de receptores intracelulares
KR20070046150A (ko) * 2004-07-28 2007-05-02 아이알엠 엘엘씨 스테로이드 호르몬 핵 수용체의 조절제로서의 화합물 및조성물
AR056893A1 (es) 2005-12-28 2007-10-31 Takeda Pharmaceutical Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
EA016370B1 (ru) 2006-10-31 2012-04-30 Пфайзер Продактс Инк. Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
JP2010522168A (ja) 2007-03-23 2010-07-01 メルク・シャープ・エンド・ドーム・コーポレイション 鉱質コルチコイドレセプターモジュレータ
PT2133330E (pt) 2007-04-09 2014-03-31 Daiichi Sankyo Co Ltd Atropisómero de derivado de pirrole
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
UY31905A (es) * 2008-06-18 2010-01-29 Astrazeneca Ab Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
JP2012523405A (ja) 2009-04-10 2012-10-04 ファイザー・インク ４，５−ジヒドロ−１ｈ−ピラゾール化合物およびその薬学的使用
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
CN102906495B (zh) 2010-05-11 2016-08-24 皇家飞利浦电子股份有限公司 照明模块
US20130116227A1 (en) 2010-07-13 2013-05-09 Dainippon Sumitomo Pharma Co., Ltd. Biaryl amide derivative or pharmaceutically acceptable salt thereof
US8722709B2 (en) 2010-11-10 2014-05-13 Boehringer Ingelheim International Gmbh Mineralocorticoid receptor antagonists
DK3160948T3 (en) * 2014-06-30 2019-02-18 Astrazeneca Ab BENZOXAZINONAMIDES AS MODULATORS OF MINERALOCORTICOID RECEPTORS

Also Published As

Publication number Publication date
TWI677498B (zh) 2019-11-21
ES2707726T3 (es) 2019-04-04
KR20170021883A (ko) 2017-02-28
CA2953655A1 (en) 2016-01-07
CN106536491A (zh) 2017-03-22
CN106536491B (zh) 2018-12-18
TW201613909A (en) 2016-04-16
AU2015282450C1 (en) 2018-09-20
PL3160948T3 (pl) 2019-04-30
HUE042370T2 (hu) 2019-06-28
EP3160948A1 (en) 2017-05-03
AU2015282450B2 (en) 2018-05-10
DK3160948T3 (en) 2019-02-18
US10017502B2 (en) 2018-07-10
EA029518B1 (ru) 2018-04-30
AR101036A1 (es) 2016-11-16
MX2017000183A (es) 2017-04-25
ME03316B (me) 2019-10-20
KR102012222B1 (ko) 2019-10-21
US9394291B2 (en) 2016-07-19
PT3160948T (pt) 2019-02-01
UY36195A (es) 2016-01-08
LT3160948T (lt) 2019-02-11
RS58274B1 (sr) 2019-03-29
AU2015282450A1 (en) 2017-02-02
WO2016001631A1 (en) 2016-01-07
TR201900659T4 (tr) 2019-02-21
CA2953655C (en) 2020-05-12
JP2017522300A (ja) 2017-08-10
EP3160948B1 (en) 2018-10-24
HRP20190147T1 (hr) 2019-03-22
SI3160948T1 (sl) 2020-06-30
US20170217945A1 (en) 2017-08-03
US20150376170A1 (en) 2015-12-31
JP6368383B2 (ja) 2018-08-01
MX367404B (es) 2019-08-20
EA201790046A1 (ru) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CL2017001061A1 (es) Cromanos sustituidos y métodos para su uso
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
CY1120340T1 (el) Gpr40 ρυθμιστες πυρρολιδινης για τη θεραπεια ασθενειων οπως διαβητη
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
EA201791304A1 (ru) Производные изохинолина для лечения вич
CY1124059T1 (el) Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1123576T1 (el) Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
CY1122321T1 (el) Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
EA201692298A1 (ru) Производные карбоксамидов
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CY1123185T1 (el) Παραγωγα ινδολιου
MX2016014118A (es) Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
EA201990723A1 (ru) Кристаллические формы
CY1118920T1 (el) Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7